Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 3/2013

01-03-2013 | Interventional

Placement of retrievable self-expandable metallic stents with barbs into patients with obstructive prostate cancer

Authors: Ho-Young Song, Choung Soo Kim, In Gab Jeong, Dalsan Yoo, Jin Hyoung Kim, Deok Ho Nam, Jae-Ik Bae, Jung-Hoon Park

Published in: European Radiology | Issue 3/2013

Login to get access

Abstract

Objectives

To evaluate the technical feasibility and clinical effectiveness of retrievable self-expandable metallic stents with barbs in patients with obstructive prostate cancer.

Methods

Retrievable self-expandable metallic stents with eight barbs each were inserted into eight consecutive patients with obstructive prostate cancer. Patient ages ranged from 55 to 76 years (mean, 69 years). All eight patients had previously received hormone therapy, and three had undergone palliative transurethral prostatectomy. Stents were removed using a 21-F stent removal set if they caused complications.

Results

Stent placement was technically successful and well tolerated in all patients. One had severe incontinence, which improved spontaneously, and two had gross haematuria, which disappeared spontaneously within 4 days. Peak urine flow rates and post-void residual urine volumes 1 month after stent placement were 5.6–10.2 ml/s (mean, 8.3 ml/s), and 5–45 ml (mean, 27 ml), respectively. During a mean follow-up of 192 days (range, 39–632 days), one patient required stent removal after 232 days because of stone formation within the stent. No further intervention was required because the mass improved after stent removal.

Conclusions

These preliminary results suggest that retrievable stents with eight barbs are both feasible to place and effective in patients with obstructive prostate cancer.

Key Points

• Retrievable metallic urethral stents can help patients with obstructive prostate cancer.
• Retrievable self-expandable stents with eight barbs are both feasible and effective.
• These stents apparently overcome the problem of stent migration.
• Removal of these stents was safe without surgery under local anaesthesia.
Literature
1.
Crain DS, Amling CL, Kane CJ (2004) Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer. J Urol 171:668–671PubMedCrossRef
2.
3.
McGowan DG (1980) The adverse influence of prior transurethral resection on prognosis in carcinoma of the prostate treated by radiation therapy. Int J Radiat Oncol Biol Phys 6:1121–1126PubMedCrossRef
4.
Hanks GE, Leibel S, Kramer S (1983) The dissemination of cancer by transurethral resection of locally advanced prostate cancer. J Urol 129:309–311PubMed
5.
Forman JD, Order SE, Zinreich ES et al (1986) The correlation of pretreatment transurethral resection of prostatic cancer with tumour dissemination and disease-free survival. A univariate and multivariate analysis. Cancer 58:1770–1778PubMedCrossRef
6.
Krupski TL, Stukenborg GJ, Moon K, Theodorescu D (2010) The relationship of palliative transurethral resection of the prostate with disease progression in patients with prostate cancer. BJU Int 106:1477–1483PubMedCrossRef
7.
Song HY, Do YS, Han YM et al (1994) Covered, expandable esophageal metallic stent tubes: experiences in 119 patients. Radiology 193:689–695PubMed
8.
Kim JH, Song HY, Shin JH et al (2007) Metallic stent placement in the palliative treatment of malignant gastroduodenal obstructions: prospective evaluation of results and factors influencing outcome in 213 patients. Gastrointest Endosc 66:256–264PubMedCrossRef
9.
Ornellas LC, Stefanidis G, Chuttani R, Gelrud A, Kelleher TB, Pleskow DK (2009) Covered Wallstents for palliation of malignant biliary obstruction: primary stent placement versus reintervention. Gastrointest Endosc 70:676–683PubMedCrossRef
10.
Kim CS, Song HY, Jeong IG et al (2011) Temporary placement of covered retrievable expandable nitinol stents with barbs in high-risk surgical patients with benign prostatic hyperplasia: work in progress. J Vasc Interv Radiol 22:1420–1426PubMedCrossRef
11.
Barry MJ, Fowler FJ Jr, O’Leary MP et al (1992) The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148:1549–1557PubMed
12.
Antonarakis ES, Eisenberger MA (2011) Expanding treatment options for metastatic prostate cancer. N Engl J Med 364:2055–2058PubMedCrossRef
13.
Oefelein MG (2004) Prognostic significance of obstructive uropathy in advanced prostate cancer. Urology 63:1117–1121PubMedCrossRef
14.
Chapple CR, Milroy EJG, Rickards D (1990) Permanently implanted urethral stent for prostatic obstruction in the unfit patient. Preliminary report. Br J Urol 66:58–65PubMedCrossRef
15.
McLouglin J, Jager R, Abel PD, Williams G (1990) The use of prostatic stents in patients with urinary retention who are unfit for surgery. An interim report. Br J Urol 66:66–70CrossRef
16.
Williams G, Coulange C, Milroy EJG, Sarramon JP, Rubben H (1993) The Urolume, a permanently implanted prostatic stent for patients at high risk for surgery. Results from 5 collaborative centres. Br J Urol 72:335–340PubMed
17.
Milroy E, Chapple CR (1993) The Urolume stent in the management of benign prostatic hyperplasia. J Urol 150:1630–1635PubMed
18.
Oesterling JE, Kaplan SA, Epstein HB, Defalco AJ, Reddy PK, Chancellor MB (1994) The North American experience with the UroLume endoprosthesis as a treatment for benign prostatic hyperplasia: long-term results. The North American UroLume Study Group. Urology 44:353–362PubMedCrossRef
19.
Masood S, Djaladat H, Kouriefs C, Keen M, Palmer JH (2004) The 12-year outcome analysis of an endourethral wallstent for treating benign prostatic hyperplasia. BJU Int 94:1271–1274PubMedCrossRef
20.
Shah DK, Kapoor R, Badlani GH (2003) Experience with urethral stent explantation. J Urol 169:1398–1400PubMedCrossRef
21.
Armitage JN, Cathcart PJ, Rashidian A, De Nigris E, Emberton M, van der Meulen JH (2007) Epithelializing stent for benign prostatic hyperplasia: a systematic review of the literature. J Urol 177:1619–1624PubMedCrossRef
22.
Song HY, Cho KS, Sung KB, Han YM, Kim YG, Kim CS (1995) Self-expandable metallic stents in high-risk patients with benign prostatic hyperplasia: long-term follow-up. Radiology 195:655–660PubMed
23.
van Dijk MM, Mochtar CA, Wijkstra H, Laguna MP, de la Rosette JJ (2006) The bellshaped nitinol prostatic stent in the treatment of lower urinary tract symptoms: experience in 108 patients. Eur Urol 49:353–359PubMedCrossRef
24.
Yoon CJ, Song HY, Kim JH et al (2010) Temporary placement of a covered, retrievable, barbed stent for the treatment of hormone-induced benign prostatic hyperplasia: technical feasibility and histologic changes in canine prostates. J Vasc Interv Radiol 21:1429–1435PubMedCrossRef
25.
Crisostomo V, Song HY, Maynar M, Sun F, Soria F, Lima JR, Yoon CJ (2007) Evaluation of the effects of temporary covered nitinol stent placement in the prostatic urethra: short-term study in the canine model. Cardiovasc Intervent Radiol 30:731–737PubMedCrossRef
Metadata
Title
Placement of retrievable self-expandable metallic stents with barbs into patients with obstructive prostate cancer
Authors
Ho-Young Song
Choung Soo Kim
In Gab Jeong
Dalsan Yoo
Jin Hyoung Kim
Deok Ho Nam
Jae-Ik Bae
Jung-Hoon Park
Publication date
01-03-2013
Publisher
Springer-Verlag
Published in
European Radiology / Issue 3/2013
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-012-2650-8

Other articles of this Issue 3/2013

European Radiology 3/2013 Go to the issue

Chest

Morphological changes of the thoracic duct and accessory lymphatic channels in patients with chylothorax: detection with unenhanced magnetic resonance imaging

Interventional

How to design the optimal self-expandable oesophageal metallic stents: 22 years of experience in 645 patients with malignant strictures

Computed Tomography

Diagnostic accuracy of 128-slice dual-source CT coronary angiography: a randomized comparison of different acquisition protocols

Magnetic Resonance

MRI-based biodistribution assessment of holmium-166 poly(L-lactic acid) microspheres after radioembolisation

Oncology

Grading of uterine cervical cancer by using the ADC difference value and its correlation with microvascular density and vascular endothelial growth factor

Breast

Novel technology of multimodal ultrasound tomography detects breast lesions